Solventum Corporation (SOLV)

NYSE: SOLV · USD

$81.7

-1.24 (-1.5%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-10-14

Our latest published analysis: SOLV rated Buy

Solventum Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$104 / share

Potential value

$130 / share

Upside to FV

+19.7%

from $81.7

Moat

7.2/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$14.7B
Revenue (ttm)	8.3B
Net income (ttm)	1.4B
EPS (ttm)	$8.19
Shares out	170.2M
P/E (trailing)	10.0x
P/E (forward)	13.1x
Volume	1,130,124
Beta	0.70

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 8.3B
Net income (ttm): 1.4B
EPS (ttm): $8.19
P/E (trailing): 10.0x
P/E (forward): 13.1x
Market cap: $14.7B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$8.17B	$8.13B	$8.20B	$8.25B	$8.33B	+0.5%
Gross profit	$4.92B	$4.70B	$4.69B	$4.59B	$4.45B	-2.5%
Operating income	$1.88B	$1.69B	$1.69B	$1.04B	$2.18B	+3.8%
Net income	$1.46B	$1.34B	$1.35B	$479.0M	$1.56B	+1.6%
EPS (diluted)	—	$7.78	$7.79	$2.76	$8.88	+4.5%
EBITDA	$2.48B	$2.27B	$2.23B	$1.53B	$2.55B	+0.7%
R&D	$766.0M	$767.0M	$758.0M	$775.0M	$739.0M	-0.9%
SG&A	$2.28B	$2.24B	$2.30B	$2.78B	$3.08B	+7.8%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Base55%

Price target

$103.66

+19.7% from spot

In the Base case (55% probability), Solventum executes against its post-spin operating schedule. Transitory Q3 2026 order reversals normalize into positive organic growth in Q4 (3% to 4%), yielding full-year FY2026 organic growth of 2.5% to 3.0%. Operating margins expand from 22.5% to 23.8% over five years, driving EPS to $8.21 by FY2030. Intrinsic fair value settles at $103.66.

Organic revenue growth normalizing to 3.56% in FY2027 and 3.0% by FY2029
Operating margins expanding from 22.5% in FY2026 to 23.8% in FY2030
Adjusted diluted EPS compounding from $7.14 in FY2026 to $7.23 in FY2027 and $8.21 in FY2030
WACC sustained at 7.67% and terminal growth rate at 2.5%

Bull20%

Price target

$129.62

+49.7% from spot

In the Bull case (20% probability), successful North American ERP replenishment and rapid execution of the Health Information Systems separation unlock significant shareholder value,. Core MedSurg procedure growth accelerates above 4.0% as SKU rationalization concludes, and operating margins expand toward 24.5%. Cash proceeds from HIS de-lever the balance sheet and accelerate share repurchases, lifting fair value to $129.62.

Organic sales growth accelerating to 3.5%-4.0% ex-SKUs
Operating margins expanding post-separation through standalone operational efficiencies
HIS separation proceeds deployed aggressively toward debt reduction and buybacks

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($103.66). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
7.7%	$109	$111	$113	$115	$117
8.2%	$105	$106	$108	$110	$111
8.7%	$101	$102	$104	$105	$107
9.2%	$98.0	$99.0	$100	$101	$102
9.7%	$95.1	$95.9	$96.8	$97.8	$98.8

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E13.1

P25 n/aP50 n/aP75 n/a

Trailing P/E10.5

P25 n/aP50 n/aP75 n/a

ROE34

P25 n/aP50 n/aP75 n/a

ROIC5.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SOLV indicators

Market & fundamental data

Available fields

234

Groups with data

Currency

USD

Showing 234 of 234 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001964738
Company name	Solventum Corporation
Country	United States
Country code	US
CUSIP number	83444M101
Earnings date	2026-11-05
Earnings time	amc
Employees	20,584
Employees change	-1,416
Employees growth	-6.44%
Enterprise value	$18.8B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2023
In index	SP500
Industry	Medical Instruments & Supplies
Is primary listing	Yes
Is SPAC	No
ISIN number	US83444M1018
Last 10-K release date	2026-02-27
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$13.9B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$81.74
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	SOLV
U.S. state	Minnesota
Website	https://www.solventum.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	11.51x
Average P/E ratio (3Y)	16.21x
Earnings yield	10.02%
EV/Earnings	13.17x
EV/EBIT	29.84x
EV/EBITDA	16.58x
EV/Sales	2.27x
FCF / EV yield	-0.62%
FCF yield	-0.84%
Forward EV/Sales	2.26x
Forward P/E	12.07x
Forward P/S	1.67x
Graham number	72.12208
Graham upside	-12.29%
Industry forward P/E	22.82x
Industry P/E	66.22x
Lynch fair value	$40.97
Lynch upside	-50.18%
P/(OCF - SBC) ratio	333.27x
P/B ratio	2.94x
P/E ratio	9.98x
P/OCF ratio	66.97x
P/S ratio	1.68x
PEG ratio	1.18x
Price/EBITDA ratio	12.29x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	7.62%
EBITDA margin	13.71%
Effective tax rate	15.45%
Gross margin	54.78%
Operating margin	7.62%
Pretax margin	20.41%
Profit margin	17.26%
Profit per employee	$69,666
Profitable quarters	14
Profitable years	5
Revenue per employee	$403,712
ROA	2.7%
ROCE	5.98%
ROE	33.96%
ROIC	5.52%
ROIC (5Y)	9.73%
SBC / revenue	2.01%
Tax / revenue	3.15%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	275.1%
EPS growth (Q)	3.92%
EPS growth (QoQ)	657.14%
EPS growth 3Y	4.05%
EPS growth quarters	1
EPS growth years	1
FCF growth (Q)	144.07%
Gross profit growth	-1.11%
Gross profit growth (Q)	10.12%
Gross profit growth 3Y	-0.23%
Net income growth	277.37%
Net income growth (Q)	2.22%
Net income growth (QoQ)	607.69%
Net income growth 3Y	4.52%
Net income growth quarters	1
Net income growth years	1
OCF growth	-64.33%
OCF growth (Q)	34.32%
OCF growth 3Y	-51.37%
Operating income growth	-24.91%
Operating income growth (Q)	1.89%
Operating income growth 3Y	-26.39%
Revenue growth	-0.93%
Revenue growth (Q)	2.22%
Revenue growth (QoQ)	10.06%
Revenue growth 3Y	0.85%
Revenue growth quarters	1
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-327M
Depreciation and amortization	$506M
EBIT	$633M
EBITDA	$1.1B
EPS	$8.19
FCF per share	$-0.69
Financing cash flow	$-3.2B
Free cash flow	$-118M
Free cash flow minus SBC	$-285M
Gross profit	$4.6B
Income taxes	$262M
Investing cash flow	$2.9B
Net borrowing	$-2.8B
Net cash flow	$-89M
Net income	$1.4B
Operating cash flow minus SBC	$42M
Operating income	$633M
Revenue	$8.3B
Stock-based compensation	$167M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.74
Book value per share	$28.22
Debt / EBITDA	4.2
Debt / equity	1.1
Goodwill	$5.6B
Interest coverage	2.39
Long-term assets	$10.5B
Long-term liabilities	$5.8B
Net cash (debt)	$-4.9B
Net cash / market cap	-34.95%
Net debt / EBITDA	4.3
Net debt / equity	1.02
Piotroski F-Score	5
Property, plant and equipment	$1.8B
Shareholders' equity	$4.8B
Tangible book value	$-3.2B
Tangible book value per share	$-19.01
Total assets	$14.2B
Total cash	$403M
Total debt	$5.3B
Total liabilities	$9.4B
WACC	7.05%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.57
Current assets	$3.7B
Current liabilities	$3.7B
Current ratio	1.02
Inventory turnover	3.75
Net working capital	$183M
Quick ratio	0.5
Working capital	$78M
Working capital turnover	24.95

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.2%
Dividend yield	0%
Shareholder yield	-0.2%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$79.86
1D price change	-1.49%
1M price change	-8.87%
1M total return	-8.87%
1W price change	-5.89%
1W total return	-5.89%
1Y price change	13.32%
1Y return CAGR	13.33%
1Y total return	13.32%
20-day SMA	$86.21
200-day SMA	$78.34
3M price change	1.36%
3M total return	1.36%
50-day SMA	$88.32
50-day SMA vs 200-day SMA	50over200
52-week high	$94.16
52-week high date	2026-09-01
52-week low	$62.38
52-week low date	2026-04-07
6M price change	16.89%
6M total return	16.89%
All-time high	$96.05
All-time high date	2024-03-26
All-time low	$47.16
All-time low date	2024-07-16
Average true range (ATR)	$2.11
Average volume	1M
Beta (1Y)	0.4
Beta (2Y)	0.77
Beta (5Y)	0.7
Change from 52-week high	-13.19%
Change from 52-week low	31.04%
Change from all-time high	-15.08%
Change from all-time low	72.95%
Change from open	-1.79%
Day's gap	0.3%
Dollar volume	$92.4M
High price	$83.23
Low price	$81.46
Monthly RSI	55.37
Open price	$83.23
Position in 52-week range	15.82%
Premarket change	-0.46%
Premarket close	$82.98
Premarket price	$82.60
Premarket volume	1.2K
Previous close	$82.98
Price vs 150-day SMA	2.14%
Price vs 20-day SMA	-5.38%
Price vs 200-day SMA	4.11%
Price vs 50-day SMA	-7.65%
Relative volume	1.1
RSI	32.72
Sharpe ratio	0.43
Sortino ratio	0.85
Volume	1.1M
Weekly RSI	47.88
YTD price change	2.93%
YTD total return	2.93%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	144.1M
Float percentage	84.65%
Shares change (QoQ)	-1.25%
Shares change (YoY)	0.2%
Shares held by insiders	0.26%
Shares held by institutions	77.69%
Shares outstanding	170.2M
Short % of float	3.4%
Short % of shares	2.88%
Short ratio	5.6 days

Deeper analysis on SOLV

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this SOLV report

What is the latest published SOLV stock rating?

Solventum Corporation is shown with Buy in the latest published report, analyzed 2026-10-14. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full SOLV analysis?

The full latest published report, analyzed 2026-10-14, lives at /stocks/SOLV/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for SOLV?

The latest published report analyzed 2026-10-14 gives SOLV a fair value of USD 104 and a potential value of USD 130. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the SOLV page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-14). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BuySOLV · Fair value $104+19.7%

Read full analysis →

Solventum Corporation (SOLV)

Our latest published analysis: SOLV rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · SOLV

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All SOLV indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SOLV

Frequently asked questions

评级历史

Category	Score	Reading
Valuation	7.5
Management	7.5
Balance Sheet	5.0
Profitability	7.5
Revenue Growth	4.5
Risk Assessment	7.0
Competitive Moat	7.2
Earnings Quality	3.0
Capital Efficiency	2.5